Vertex Pharmaceuticals Inc
VRTX: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|&$ | LOCK|<^&Q | LOCK|PB&N@! |
Vertex Earnings: Diversification Beyond CF Strengthens Long-Term Growth Outlook
Vertex reported third-quarter revenue of $3.4 billion, up 12% year over year, driven by continued growth in its cystic fibrosis franchise, which accounted for 95% of total product revenue. Vertex raised its 2026 revenue growth outlook by 38 basis points at the midpoint.
